{
  "$schema": "./OSP_Qualification_Plan_Schema.json",
  "Projects": [
    {
      "Id": "Mefenamic_acid",
      "Path": "https://raw.githubusercontent.com/Open-Systems-Pharmacology/Mefenamic-acid-Model/v1.1/Mefenamic_acid-Model.json",
      "BuildingBlocks": []
    },
    {
      "Id": "Dapagliflozin",
      "Path": "https://raw.githubusercontent.com/Open-Systems-Pharmacology/Dapagliflozin-Model/v1.1/Dapagliflozin-Model.json",
      "BuildingBlocks": []
    },
    {
      "Id": "Raltegravir",
      "Path": "https://raw.githubusercontent.com/Open-Systems-Pharmacology/Raltegravir-Model/v1.2/Raltegravir-Model.json",
      "BuildingBlocks": []
    },
    {
      "Id": "Atazanavir",
      "Path": "https://raw.githubusercontent.com/Open-Systems-Pharmacology/Atazanavir-Model/v1.1/Atazanavir-Model.json",
      "BuildingBlocks": []
    },
    {
      "Id": "Mefenamic_acid-Dapagliflozin-DDI",
      "Path": "https://raw.githubusercontent.com/Open-Systems-Pharmacology/Mefenamic_acid-Dapagliflozin-DDI/v1.1/Mefenamic_acid-Dapagliflozin-DDI.json",
      "BuildingBlocks": [
        {
          "Type": "Individual",
          "Name": "Standard_Adult_UGT",
          "Project": "Dapagliflozin"
        },
        {
          "Type": "Compound",
          "Name": "Mefenamic acid",
          "Project": "Mefenamic_acid"
        },
        {
          "Type": "Compound",
          "Name": "Dapagliflozin",
          "Project": "Dapagliflozin"
        },
        {
          "Type": "Formulation",
          "Name": "Ponstan capsule",
          "Project": "Mefenamic_acid"
        }
      ],
      "SimulationParameters": [
        {
          "Project": "Dapagliflozin",
          "Simulation": "PO SD 10 mg (perm)",
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "TargetSimulations": [
            "DDI Control - Dapagliflozin - Kasichayanula 2013a",
            "DDI Treatment - Mefenamic acid/Dapagliflozin - Kasichayanula 2013a"
          ]
        },
        {
          "Project": "Dapagliflozin",
          "Simulation": "PO SD 10 mg (perm)",
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "TargetSimulations": [
            "DDI Control - Dapagliflozin - Kasichayanula 2013a",
            "DDI Treatment - Mefenamic acid/Dapagliflozin - Kasichayanula 2013a"
          ]
        }
      ]
    },
    {
      "Id": "Atazanavir-Raltegravir-DDI",
      "Path": "https://raw.githubusercontent.com/Open-Systems-Pharmacology/Atazanavir-Raltegravir-DDI/v1.1/Atazanavir-Raltegravir-DDI.json",
      "BuildingBlocks": [
        {
          "Type": "Compound",
          "Name": "Raltegravir",
          "Project": "Raltegravir"
        },
        {
          "Type": "Compound",
          "Name": "Atazanavir",
          "Project": "Atazanavir"
        },
        {
          "Type": "Formulation",
          "Name": "Reyataz capsule",
          "Project": "Atazanavir"
        },
        {
          "Type": "Formulation",
          "Name": "filmcoated tablet (original Merck formulation)",
          "Project": "Raltegravir"
        }
      ]
    }
  ],
  "ObservedDataSets": [
    {
      "Id": "DDI Ratios",
      "Path": "DDI.csv",
      "Type": "DDIRatio"
    }
  ],
  "Plots": {
    "PlotSettings": {
      "ChartWidth": 500,
      "ChartHeight": 400,
      "Fonts": {
        "AxisSize": 11,
        "LegendSize": 9,
        "OriginSize": 9,
        "FontFamilyName": "Arial",
        "WatermarkSize": 40
      }
    },
    "AxesSettings": {
      "ComparisonTimeProfile": [
        {
          "Unit": "h",
          "Dimension": "Time",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Linear"
        },
        {
          "Unit": "ng/ml",
          "Dimension": "Concentration (mass)",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ],
      "DDIRatioPlotsPredictedVsObserved": [
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ],
      "DDIRatioPlotsResidualsVsObserved": [
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ]
    },
    "ComparisonTimeProfilePlots": [
      {
        "SectionReference": "atazanavir-raltegravir-ddi",
        "Title": "Iwamoto 2008",
        "SimulationDuration": 176,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Iwamoto2008_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Iwamoto 2008 - Study I, Period 1 (control) - Raltegravir - PO - 100 mg - Plasma - agg. (n=10)",
            "StartTime": 0,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Iwamoto2008_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Iwamoto 2008 - Study I, Period 2 (ATV treatment) - Raltegravir - PO - 100 mg - Plasma - agg. (n=10)",
            "StartTime": 144,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      },
      {
        "SectionReference": "atazanavir-raltegravir-ddi",
        "Title": "Krishna 2016",
        "SimulationDuration": 216,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Krishna2016_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Krishna 2016 - Period 1, Day 1 (1200 mg raltegravir SD) - Raltegravir - PO - 1200 mg - Plasma - agg. (n=14)",
            "StartTime": 0,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Krishna2016_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Krishna 2016 - Period 2, Day 7 (1200 mg raltegravir SD with OD doses of 400 mg ATV) - Raltegravir - PO - 1200 mg - Plasma - agg. (n=12)",
            "StartTime": 144,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      },
      {
        "SectionReference": "atazanavir-raltegravir-ddi",
        "Title": "Neely 2010",
        "SimulationDuration": 192,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Neely2010_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Neely 2010 - Study arm A (Raltegravir 400mg BID) - Raltegravir - PO - 400 mg - Plasma - agg. (n=20)",
            "StartTime": 168,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Neely2010_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Neely 2010 - Study arm B (Raltegravir 400mg OD + Atazanavir 400 mg OD) - Raltegravir - PO - 400 mg - Plasma - agg. (n=19)",
            "StartTime": 168,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      },
      {
        "SectionReference": "atazanavir-raltegravir-ddi",
        "Title": "Zhu 2010",
        "SimulationDuration": 612,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Zhu2010_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Zhu 2010 - Raltegravir 400 mg twice daily - Raltegravir - PO - 400 mg - Plasma - agg. (n=22)",
            "StartTime": 96,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Zhu2010_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Zhu 2010 - Raltegravir 400 mg twice daily plus atazanavir 300 mg twice daily - Raltegravir - PO - 400 mg - Plasma - agg. (n=19)",
            "StartTime": 600,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      },
      {
        "SectionReference": "mefenamic-acid-dapagliflozin-ddi",
        "Title": "Kasichayanula 2013a",
        "SimulationDuration": 48,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Mefenamic_acid-Dapagliflozin-DDI",
            "Simulation": "DDI Control - Dapagliflozin - Kasichayanula 2013a",
            "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)",
            "StartTime": 0,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without mefenamic acid)",
            "Symbol": "Circle"
          },
          {
            "Project": "Mefenamic_acid-Dapagliflozin-DDI",
            "Simulation": "DDI Treatment - Mefenamic acid/Dapagliflozin - Kasichayanula 2013a",
            "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Kasichayanula 2013a - Study 2: with Perpetrator (Mefenamic Acid) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)",
            "StartTime": 24,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with mefenamic acid)",
            "Symbol": "Square"
          }
        ]
      }
    ],
    "DDIRatioPlots": [
      {
        "SectionReference": "qualification-of-use-case-ugt-mediated-ddi",
        "Title": "UGT1A1 and UGT1A9 Inhibition DDI",
        "PKParameters": [
          "AUC",
          "CMAX"
        ],
        "PlotTypes": [
          "predictedVsObserved",
          "residualsVsObserved"
        ],
        "Subunits": [
          "Mechanism",
          "Perpetrator",
          "Victim"
        ],
        "Artifacts": [
          "Plot",
          "GMFE",
          "Measure",
          "Table"
        ],
        "Groups": [
          {
            "Caption": "Atazanavir + Raltegravir",
            "Color": "#b2182b",
            "Symbol": "Circle",
            "DDIRatios": [
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 571,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Iwamoto2008_Raltegravir",
                  "StartTime": 0,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Iwamoto2008_Raltegravir+Atazanavir",
                  "StartTime": 144,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                }
              },
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 575,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Krishna2016_Raltegravir",
                  "StartTime": 0,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Krishna2016_Raltegravir+Atazanavir",
                  "StartTime": 144,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                }
              },
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 573,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Neely2010_Raltegravir",
                  "StartTime": 168,
                  "EndTime": 180,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Neely2010_Raltegravir+Atazanavir",
                  "StartTime": 168,
                  "EndTime": 192,
                  "TimeUnit": "h"
                }
              },
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 579,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Zhu2010_Raltegravir",
                  "StartTime": 96,
                  "EndTime": 108,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Zhu2010_Raltegravir+Atazanavir",
                  "StartTime": 600,
                  "EndTime": 612,
                  "TimeUnit": "h"
                }
              }
            ]
          },
          {
            "Caption": "Mefenamic acid + Dapagliflozin",
            "Color": "#2166ac",
            "Symbol": "Square",
            "DDIRatios": [
              {
                "Output": "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 642,
                "SimulationControl": {
                  "Project": "Mefenamic_acid-Dapagliflozin-DDI",
                  "Simulation": "DDI Control - Dapagliflozin - Kasichayanula 2013a",
                  "StartTime": 0,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Mefenamic_acid-Dapagliflozin-DDI",
                  "Simulation": "DDI Treatment - Mefenamic acid/Dapagliflozin - Kasichayanula 2013a",
                  "StartTime": 24,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                }
              }
            ]
          }
        ]
      }
    ]
  },
  "Inputs": [],
  "Sections": [
    {
      "Reference": "introduction",
      "Title": "Introduction",
      "Sections": [
        {
          "Reference": "objective",
          "Title": "Objective",
          "Content": "Content/Qualification_DDI_UGT_objective.md"
        },
        {
          "Reference": "ugt-ddi-network",
          "Title": "UGT DDI Network",
          "Content": "Content/Qualification_DDI_UGT_network_description.md",
          "Sections": [
            {
              "Title": "Atazanavir - Raltegravir DDI",
              "Content": "Content/ATV-RAL-DDI.md"
            },
            {
              "Title": "Mefenamic acid - Dapagliflozin DDI",
              "Content": "Content/MEFA-Dapa-DDI.md"
            }
          ]
        }
      ]
    },
    {
      "Reference": "qualification-of-use-case-ugt-mediated-ddi",
      "Title": "Qualification of Use Case UGT-mediated DDI"
    },
    {
      "Reference": "ct-profiles",
      "Title": "Concentration-Time Profiles",
      "Content": "Content/Intro_evaluation_DDI_network.md",
      "Sections": [
        {
          "Reference": "atazanavir-raltegravir-ddi",
          "Title": "Atazanavir - Raltegravir DDI"
        },
        {
          "Reference": "mefenamic-acid-dapagliflozin-ddi",
          "Title": "Mefenamic acid - Dapagliflozin DDI"
        }
      ]
    },
    {
      "Reference": "references",
      "Title": "References",
      "Content": "Content/References.md",
      "Sections": []
    },
    {
      "Reference": "appendix",
      "Title": "Appendix",
      "Sections": [
        {
          "Reference": "osps-introduction",
          "Title": "Open Systems Pharmacology Suite (OSPS) Introduction",
          "Content": "Content/OSPS_Introduction.md"
        },
        {
          "Reference": "mathematical-implementation-of-ddi",
          "Title": "Mathematical Implementation of Drug-Drug Interactions",
          "Content": "Content/Mathematical_Implementation_of_DDI.md"
        },
        {
          "Reference": "requalification-workflow",
          "Title": "Automatic (re)-qualification workflow",
          "Content": "Content/Qualification_Workflow.md"
        }
      ]
    }
  ],
  "Intro": [
    {
      "Path": "Content/titlepage.md"
    }
  ]
}